Cargando…

Dynamics of Antibody Response to BNT162b2 mRNA COVID-19 Vaccine: A 7-Month Follow-Up Study

Background and Objectives: Comprehension regarding immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is limited, and the durability of immune responses after vaccination is currently unknown. Several studies have reported on the antibody response in fully vaccinated individual...

Descripción completa

Detalles Bibliográficos
Autores principales:	Olariu, Tudor Rares, Ursoniu, Sorin, Marincu, Iosif, Lupu, Maria Alina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8708569/ https://www.ncbi.nlm.nih.gov/pubmed/34946275 http://dx.doi.org/10.3390/medicina57121330

Ejemplares similares

Trichinellosis in Hospitalized Children and Adults from Western Romania: A 11-Year Retrospective Study
por: Pavel, Radu, et al.
Publicado: (2023)

Seroprevalence of SARS-CoV-2 antibodies in 2115 blood donors from Romania
por: Olariu, Tudor Rares, et al.
Publicado: (2021)

SARS-CoV-2 Seroprevalence in Western Romania, March to June 2021
por: Olariu, Tudor Rares, et al.
Publicado: (2021)

Seroprevalence and Risk Factors of Trichinella spiralis Infection in Blood Donors from Western Romania
por: Pavel, Radu, et al.
Publicado: (2022)

Toxoplasma gondii Infection in Patients with Psychiatric Disorders from Western Romania
por: Grada, Sebastian, et al.
Publicado: (2022)

Seroepidemiology of Toxoplasma gondii Infection in Blood Donors from Western Romania
por: Lupu, Maria Alina, et al.
Publicado: (2022)

Longitudinal Analysis of Antibody Responses to the mRNA BNT162b2 Vaccine in Patients Undergoing Maintenance Hemodialysis: A 6-Month Follow-Up
por: Weigert, André, et al.
Publicado: (2021)

SARS-CoV-2 antibody response after BNT162b2 mRNA vaccine in healthcare workers: Nine-month of follow-up
por: Mastroianni, Franco, et al.
Publicado: (2022)

Beyond neutralization for BNT162b2 mRNA vaccination
por: Damani-Yokota, Payal, et al.
Publicado: (2021)

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months
por: Thomas, Stephen J., et al.
Publicado: (2021)

Blood Antibody Titers and Adverse Reactions after BNT162b2 mRNA Vaccination
por: Kiewisz, Jolanta, et al.
Publicado: (2022)

Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-up
por: Canetti, Michal, et al.
Publicado: (2022)

Six-month antibody persistence after BNT162b2 mRNA COVID-19 vaccination in patients with chronic lymphocytic leukemia
por: Herishanu, Yair, et al.
Publicado: (2022)

Safety and BNT162b2 mRNA COVID-19 vaccination
por: Joob, Beuy, et al.
Publicado: (2021)

Effectiveness of mRNA-1273 and BNT162b2 Vaccines in Qatar
por: Abu-Raddad, Laith J., et al.
Publicado: (2022)

Response to BNT162b2 mRNA COVID-19 vaccine among healthcare workers in Italy: a 3-month follow-up
por: Ponticelli, Domenico, et al.
Publicado: (2021)

Impact of tozinameran (BNT162b2) mRNA vaccine on kidney transplant and chronic dialysis patients: 3–5 months follow-up
por: Ben-Dov, Iddo Z., et al.
Publicado: (2022)

BNT162b2 mRNA vaccine elicited antibody response in blood and milk of breastfeeding women
por: Rosenberg-Friedman, Michal, et al.
Publicado: (2021)

Evaluation of antibody response to BNT162b2 mRNA COVID-19 vaccine in patients affected by immune-mediated inflammatory diseases up to 5 months after vaccination
por: Firinu, Davide, et al.
Publicado: (2021)

Antibody titres decline 3-month post-vaccination with BNT162b2
por: Favresse, Julien, et al.
Publicado: (2021)

Detection of SARS-CoV-2 antibodies formed in response to the BNT162b2 and mRNA-1237 mRNA vaccine by commercial antibody tests
por: Kanji, Jamil N., et al.
Publicado: (2021)

B-cell responses to vaccination with BNT162b2 and mRNA-1273 6 months after second dose
por: Markewitz, Robert, et al.
Publicado: (2022)

CMR Imaging 6 Months After Myocarditis Associated with the BNT162b2 mRNA COVID-19 Vaccine
por: Amir, Gabriel, et al.
Publicado: (2022)

Response to BNT162b2 mRNA COVID-19 vaccine among healthcare workers in Italy: a 3-month follow-up—Reply
por: Ferrara, Pietro, et al.
Publicado: (2022)

Response to BNT162b2 mRNA COVID-19 vaccine among healthcare workers in Italy: a 3-month follow-up: comment
por: Serraino, Cristina, et al.
Publicado: (2022)

Effect of SARS-CoV-2 BNT162b2 mRNA vaccine on thyroid autoimmunity: A twelve-month follow-up study
por: Morita, Shuhei, et al.
Publicado: (2023)

Author Correction: Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-up
por: Canetti, Michal, et al.
Publicado: (2023)

mRNA-1273 but not BNT162b2 induces antibodies against polyethylene glycol (PEG) contained in mRNA-based vaccine formulations
por: Carreño, Juan Manuel, et al.
Publicado: (2022)

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
por: Polack, Fernando P., et al.
Publicado: (2020)

BNT162b2 mRNA COVID-19 Vaccine: First Approval
por: Lamb, Yvette N.
Publicado: (2021)

Delayed large pruritic eruption to the BNT162b2 mRNA vaccine
por: Terashima, Takeshi
Publicado: (2021)

Dermatomyositis Following BNT162b2 mRNA COVID-19 Vaccination
por: Gouda, Wesam, et al.
Publicado: (2022)

Central serous chorioretinopathy following the BNT162b2 mRNA vaccine
por: Hanhart, J., et al.
Publicado: (2022)

Addendum: Systems vaccinology of the BNT162b2 mRNA vaccine in humans
por: Arunachalam, Prabhu S., et al.
Publicado: (2023)

Adverse reactions to the BNT162b2 and mRNA-1273 mRNA COVID-19 vaccines in Japan
por: Kitagawa, Hiroki, et al.
Publicado: (2022)

Screening for the Detection of Toxoplasma gondii IgG, IgM and IgA in Females of Reproductive Age from Western Romania
por: Mihu, Alin Gabriel, et al.
Publicado: (2022)

Sperm quality is not affected by the BNT162b2 mRNA SARS-CoV-2 vaccine: results of a 6–14 months follow-up
por: Karavani, Gilad, et al.
Publicado: (2022)

Erratum: Effect of SARS-CoV-2 BNT162b2 mRNA vaccine on thyroid autoimmunity: a twelve-month follow-up study
Publicado: (2023)

Comparative 6-Month Wild-Type and Delta-Variant Antibody Levels and Surrogate Neutralization for Adults Vaccinated with BNT162b2 versus mRNA-1273
por: Grunau, Brian, et al.
Publicado: (2022)

Antibody maintenance and breakthrough infections 6 months after complete COVID-19 vaccination with the mRNA-1273 and BNT162b2 vaccines in hemodialysis patients
por: Rodríguez-Espinosa, Diana, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4de4b2an4cqihukmpcldqe0k9j